Peter W. Ketch

Peter W. Ketch

Auto-generated profile, based on publicly available information

Peter W. Ketch

The University of Alabama at Birmingham, School of Medicine, Birmingham, AL

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2024 in Expert Opinion on Pharmacotherapy
Verified
Journal Article
Closed access
PKPeter W. Ketch
Peter W. Ketch
RZRennan S. Zaharias
Rennan S. Zaharias
CLCharles A. Leath
Charles A. Leath
Cervical cancer, while highly preventable, remains an international public health challenge especially in under resourced regions. Although early-stage cervix confined cancers are often amenable to surgical resection, larger tumors deemed locally advanced cervical cancer (LACC) necessitate systemic therapy as part of chemoradiation therapy. Moreover, systemic therapy is the standard therapeutic approach for those presenting with primary metastasis or recurrence. While several agents have been approved to treat recurrent cervical cancer including checkpoint inhibitors as well as both biomarker agnostic and specific antibody drug conjugates, the development of agents added to chemoradiation has been less fruitful. Until recently, the addition of novel therapies to chemoradiation have been negative in terms of improving outcomes; however, results of a recent Phase III clinical trial (NCT04221945) in LACC demonstrated that the addition of pembrolizumab to standard of care chemoradiation was associated with an improvement in progression-free survival and resulted in an FDA approval for this therapy. This observation led to the first change in treating LACC since the early 2000's. Improvements in systemic therapy both alone and in combination with chemoradiation for cervical cancer have been realized. Ongoing research is needed for therapeutic options following immunotherapy.

1 October 2025 in JCO Precision Oncology
Verified
Journal Article
Open access
PKPeter W. Ketch
Peter W. Ketch
CSCarly Bess Scalise
Carly Bess Scalise
FRFernando Recio
Fernando Recio
TBTara Berman
Tara Berman
NHNicole Hook
Nicole Hook
MTMichael D. Toboni
Michael D. Toboni
PURPOSE: Clinical decision making for adjuvant treatment in early-stage uterine cancer (UC) following surgery is typically directed by clinicopathological risk factors. There is an unmet need for a clinically relevant biomarker to improve individualized risk stratification and help monitor response to adjuvant therapy. Here, we sought to analyze circulating tumor DNA (ctDNA) as a prognostic biomarker in patients with early-stage UC. METHODS: Retrospective analysis of ctDNA results from real-world data was performed for 61 patients (233 plasma time points) diagnosed with early-stage UC. ctDNA status and dynamics were assessed using a clinically validated, personalized, tumor-informed ctDNA assay (Signatera), and its association with recurrence-free survival (RFS) was evaluated. RESULTS: ctDNA positivity was associated with significantly reduced RFS postoperatively (hazard ratio [HR], 7.6; P = .003) and postdefinitive therapy (HR, 25.4; P = .0009) and was the most significant factor associated with recurrence when compared with other clinicopathological and molecular risk factors. Notably, of patients who recurred and for whom clinical outcomes were available, 100% were ctDNA-positive before or at the time of recurrence, whereas none of the serially ctDNA-negative patients experienced relapse. CONCLUSION: Our data demonstrate the feasibility of monitoring ctDNA in the postoperative and adjuvant settings in early-stage UC. Analysis of ctDNA, in addition to other risk factors, may help identify patients at the highest risk of recurrence, inform surveillance strategies, and support treatment decision-making for these patients.

16 May 2024 in MedEdPublish
Verified
Journal Article
Open access
PKPeter W. Ketch
Peter W. Ketch
JKJustin Kim
Justin Kim
BRBrandon M. Roane
Brandon M. Roane
KTKristin N. Taylor
Kristin N. Taylor
MLMargaret I. Liang
Margaret I. Liang
KKKenneth H. Kim
Kenneth H. Kim
Background Mentorship is critical for successful careers in academic medicine. There is a gap in the literature regarding specific qualities that make effective mentorship relationships for Obstetrics and Gynecology (OB/GYN) residents. This study aimed to identify the attributes most valued by OB/GYN residents in their mentorship relationships and to explore the factors influencing their choice of mentors. Methods We conducted a cross-sectional survey among OB/GYN residents, distributed electronically November 2021-March 2022. Demographic data, mentor qualities, satisfaction with current mentorship and mentee factors were identified. The survey incorporated questions adapted from the validated Ideal Mentor Scale assessing three mentor attributes: Integrity, Guidance, and Relationship. Data analysis involved descriptive statistics, Student’s t-tests, chi-squared tests, and Fisher’s Exact tests where appropriate. Results 48 of 60 (80%) of surveyed residents responded. Among the respondents, 72.9% were female and 29.1% identified as non-white. Integrity emerged as the most valued Ideal Mentor attribute. No statistically significant gender-based differences were observed in the preferences for mentor characteristics including gender of a mentor. Non-white respondents placed greater importance on having a mentor of the same race (p<0.01). Residents interested in subspecialties expressed a stronger preference for mentors with fellowship training (p<0.01) and shared research experiences (p=0.03). Conclusions OB/GYN residents seek mentors characterized by integrity and who are active in research and professional societies aligned with their interests. The data highlight the importance of considering race and subspecialty preferences in fostering influential and equitable mentorship for all residents.

10 August 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
CECarson Cain Edwards
Carson Cain Edwards
KTKati A. Turner
Kati A. Turner
KKKaitlyn Kincaid
Kaitlyn Kincaid
PKPeter W. Ketch
Peter W. Ketch
AWAnna Wilbanks
Anna Wilbanks
TBTeresa Boitano
Teresa Boitano
BackgroundPembrolizumab, a PD-1 immune checkpoint inhibitor, has shown promise in various cancers, but its role in ovarian cancer remains under investigation. While the current standard of care (SOC) is initially effective for epithelial ovarian cancer (EOC), approximately 70% of patients relapse within 3 years of completing upfront treatment, highlighting an unmet need for therapies that extend time to first progression. The survival benefit observed with hyperthermic intraperitoneal chemotherapy (HIPEC) at interval debulking surgery (IDS), combined with the potential for checkpoint inhibitors to augment antitumor immunity alongside cytotoxic and hyperthermic stimuli, provides the rationale for this novel trial combining neoadjuvant chemotherapy (NACT), immunotherapy, and HIPEC in the upfront treatment of advanced EOCPatients and MethodsThis double-arm, open-label phase II trial plans to enroll 40 patients. Patients with histologically confirmed diagnosis of FIGO stage III or IV EOC who is a candidate for neoadjuvant chemotherapy with planned IDS are eligible. Patients will receive pembrolizumab 200 mg in combination with carboplatin and paclitaxel for 3 21-day treatment cycles prior to IDS and 3 treatment cycles following IDS. During IDS, the first 10 patients who are eligible for HIPEC will receive 100 mg/m2 of cisplatin heated to 40-42°C intraperitoneally over 90 minutes. All patients will continue 2 years of maintenance pembrolizumab, and BRCA1/2-mutated or homologous recombination deficient patients will also receive maintenance olaparib in combination with pembrolizumab.ConclusionThe findings of this study have the potential to change clinical practice by informing potential primary and maintenance treatment options for further clinical trial assessment in advanced ovarian cancer.